Sector News

Categories

Borderless Insights

Image
The Skills-Forward Revolution:   Stretching the Boundaries of Professional Flexibility
Image
Sustainability: Business Leaders Must Secure the Long-Term Strategy Despite Short-Term Pressures
Image
Negotiating Terms with a New Employer

Perrigo to Buy Omega Pharma for $4.5 Billion

November 6, 2014
Life sciences
Perrigo Co. PLC has agreed to buy Belgium-based Omega Pharma NV in a bid to expand its portfolio of over-the-counter drugs and broaden its market presence throughout Europe.
 
The companies said the deal was valued at 3.6 billion euros, or $4.5 billion, which includes 2.48 billion euros in equity and 1.1 billion euros in debt. About 25% of the equity price will be paid in Perrigo stock to Omega founder Marc Coucke, while the remaining 75% will be funded through a combination of cash and debt, they added.
 
Perrigo said it has secured a 1.75 billion-euro bridge loan from J.P. Morgan Chase Bank and Barclays.
 
Omega, the fifth-largest entity in the $30 billion European OTC market, made about $1.6 billion in revenue in the 12-month period ended Sept. 30, the companies said. It boasts a portfolio of about 2,000 products, including treatments for colds, pain and gastrointestinal problems.
 
Perrigo said it expects the deal to be immediately accretive to its adjusted per-share earnings, with double-digit accretion coming during its 2016 fiscal year.
 
The companies expect the acquisition to close in the first quarter of next year.
 
Also Thursday, Perrigo unveiled weaker-than-expected results for the most recent quarter.
 
For the period ended Sept. 27, the company posted $96.3 million in profit, or 72 cents a share, down from $111.4 million, or $1.18 a share. Excluding certain items, per-share earnings were $1.40.
 
Net sales rose about 2% to $951.5 million.
 
Analysts polled by Thomson Reuters had projected $1.44 a share in earnings and $998 million in revenue.
 
By Michael Calia
 

comments closed

Related News

July 21, 2024

CordenPharma invests €900m in peptide platform expansion

Life sciences

CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.

Read more
July 21, 2024

DSM-Firmenich to sell MEG-3 fish oil business to KD Pharma Group

Life sciences

DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.

Read more
July 21, 2024

Veranova appoints Cécile Maupas as Senior Vice President, Chief Commercial Officer

Life sciences

Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.

Read more
More news

How can we help you?

We're easy to reach